Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from G1 Therapeutics, Inc. and Jazz Pharmaceuticals, Inc.

2nd Annual Virtual Tumor Board®: Navigating Novel Therapeutic Approaches for the Management of SCLC Across Lines of Care

Release Date: December 23, 2021
Expiration Date: December 23, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in lung cancer to discuss key clinical data leading to the availability of new anticancer and myeloprotective agents for patients with small cell lung cancer (SCLC), as well as investigational approaches that may change the future standard of care in SCLC. A series of case-based tumor board discussions are also provided to illustrate the applications of state-of-the-art regimens in a variety of clinical scenarios.

Acknowledgement of Commercial Support

This activity is supported by educational grants from G1 Therapeutics, Inc. and Jazz Pharmaceuticals, Inc.


Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists and radiation oncologists involved in the treatment and management of patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Determine how novel approaches for care have changed treatment paradigms for patients with SCLC
  • Apply clinical trial evidence to optimize the efficacy and safety of SCLC treatment approaches in multiple lines of care and a variety of real-world case-based scenarios
  • Discuss emerging strategies for the treatment of extensive- and limited-stage SCLC in the context of highly anticipated ongoing trials in the field of lung cancer management.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.


Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine, Medical Oncology
Professor of Pharmacology
Director, Center for Thoracic Cancers
Chief of Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital

Associate Cancer Center Director
Translational Science
Yale Cancer Center, Yale School of Medicine
New Haven, CT

Disclosures: Grant research support: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company; Consultant: AbbVie, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals, Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, eFFECTOR Therapeutics, Eli Lilly and Company, EMD Serono, Foundation Medicine, Genentech/Hoffmann-La Roche, Genmab, Gilead Sciences, Halozyme Therapeutics, Heat Biologics, HiberCell, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson & Johnson, Loxo Oncology, Merck & Co, Mirati Therapeutics, Nektar Therapeutics, Neon Therapeutics, NextCure, Novartis Pharmaceuticals Corporation, Ocean Biomedical, Oncternal Therapeutics, Pfizer, Refactor Health, Ribon Therapeutics, Sanofi, Seattle Genetics, Shire Pharmaceuticals, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Symphogen, Takeda Pharmaceutical Company, Tesaro, Tocagen, Ventana Medical Systems, WindMIL Therapeutics, Xencor; Other: Board Member (nonexecutive/ independent): Immunocore Holdings Ltd, Junshi Biosciences.


Alberto Chiappori, MD
Alberto Chiappori, MD
Senior Member
Department of Thoracic Oncology
Moffitt Cancer Center
Tampa, FL

Disclosures: Grant/Research Support: Bristol Myers Squibb AstraZeneca, Novartis; Consultant: AstraZeneca; Jazz, Pfizer; Speakers’ Bureau: Takeda, Amgen, Genentech, Blueprint Medicines, Johnson & Johnson; Stock/Shareholder: Merck.

W. Victoria Lai, MD
W. Victoria Lai, MD
Assistant Professor
Thoracic Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures:  W. Victoria Lai, MD, has no relevant financial relationships with ineligible companies.
Jared Weiss, MD
Jared Weiss, MD
Section Chief of Thoracic and Head/Neck Oncology
Associate Professor of Medicine
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Disclosures: Grant/Research Support: Mirati, Sumitomo Dainippon Pharma, Boehringer Ingelheim, PDS Biotech, Merck, AZ, Amgen, CareFusion, G1 Therapeutics, Immunicum, Lilly; Consultant: AZ, EMD Serono, Genentech, G1 Therapeutics, Jounce Therapeutics, AbbVie, Nanobiotix, Azitra, Lilly, Blueprint Medicines, Pfizer, Saatchi, Jazz, BI, Regeneron, Genmab, BeiGene; Stock/Shareholder: Achilles Therapeutics, Nektar Therapeutics, Vesselon, Nuvalent, Lyell Immunopharma, Inc.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By